Home › Multiple Myeloma › Illinois › Chicago
Multiple Myeloma clinical trials in Chicago, IL
24 studies for Multiple Myeloma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecruitingPhase 3
- Endeavor Health - Swedish Hospital, Chicago
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RecruitingPhase 3
- University of Illinois, Chicago
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
- Northwestern University, Chicago
- University of Chicago, Chicago
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
- University Of Illinois Medical Center, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Recruiting
- Northwestern University Feinberg School of Medicine, Chicago
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RecruitingPhase 1/2
- University of Chicago Medical Center, Chicago
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
RecruitingPhase 2
- University of Illinois Cancer Center, Chicago
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
RecruitingPhase 3
- Research Site, Chicago
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
RecruitingPhase 1
- University of Chicago Medical Center /ID# 278863, Chicago
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RecruitingPhase 1/2
- Research Site, Chicago
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Chicago
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Rush University System for Health, Chicago
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
RecruitingPhase 2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Cancer Treatment Centers of America-Chicago, Chicago
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
RecruitingPhase 2
- University of Illinois at Chicago, Chicago
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- Advocate Illinois Masonic Medical Center, Chicago
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, Chicago
Personalized Autologous Transplant for Multiple Myeloma
RecruitingPhase 1
- University Illinois Chicago, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- University of Chicago, Chicago
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RecruitingPhase 1
- University of Chicago Medical Center, Chicago
Hypofractionation (Radiation) Trial for Multiple Myeloma
RecruitingPhase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Northwestern, Chicago
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
RecruitingPhase 1
- University of Illinois Cancer Center, Chicago
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY59 studies
- Boston, MA45 studies
- Atlanta, GA42 studies
- Houston, TX39 studies
- Durham, NC36 studies
- Nashville, TN31 studies
- Denver, CO26 studies
- St. Louis, MO26 studies
- Rochester, MN25 studies
- Columbus, OH25 studies
- Milwaukee, WI23 studies
- Baldwin Park, CA23 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.